On Friday, United Continental Holdings Inc (NYSE:UAL)’s shares declined -1.97% to $60.33.
Chase Card Services, a division of JPMorgan Chase & Co. [JPM], Visa Inc. [V] and United Airlines [UAL] declared the extension of the popular United MileagePlus® credit card program. The multi-year agreements extend the more than 20-year legacy of providing exceptional benefits tailored for consumer and business cardmembers.
This extension will continue offering a rich credit card program across multiple products counting the United MileagePlus® Explorer, United MileagePlus® Explorer Business and United MileagePlus® Club cards.
Additionally, cardmembers will continue to enjoy access to exclusive events with InsideAccess.com in addition to exclusive luxury hotel and resort privileges.
United Continental Holdings, Inc., together with its auxiliaries, provides air transportation services in North America, the Asia-Pacific, Europe, the Middle East, Africa, and Latin America. It transports people and cargo through its mainline operations, which use jet aircraft with at least 118 seats, and its regional operations.
T-Mobile US Inc (NYSE:TMUS)’s shares dropped -1.50% to $41.83.
T-Mobile (TMUS) has generated returns of 31.42% in the trailing 12 months (or TTM) for investors and 3.55% in the trailing one-month period. In comparison, it generated -19.26% returns in 2014 and year-to-date (or YTD) returns of 41.86%.
In comparison, peer companies such as AT&T (T) and Verizon (VZ) have generated returns of -5.59% and -2.82%, respectively, in the trailing one-month period.
Moving averages
On August 24, 2015, the last trading price of T-Mobile (TMUS) was $38.73. The company’s stock was trading at 2.40%, 17.61%, and 21.71% above the 20-day, 50-day, and 100-day moving averages of $37.82, $32.93, and $31.82, respectively.
Moving average convergence divergence and RSI
The MACD (or moving average convergence divergence) is the difference between the short-term and long-term moving averages of a company. T-Mobile’s 14-day MACD is -1.08 for T-Mobile and shows a downward trading trend, as the figure is negative.
The 14-day relative strength index (or RSI) for T-Mobile is 40.51, which shows that the stock is slightly oversold. Generally, if the RSI is above 70, it indicates the stock is overbought, while an RSI figure below 30 suggests that a stock has been oversold.
T-Mobile US, Inc., together with its auxiliaries, provides mobile communications services in the United States, Puerto Rico, and the U.S. Virgin Islands. The company offers voice, messaging, and data services in the postpaid, prepaid, and wholesale markets. It also provides wireless devices, such as smartphones, tablets, and other mobile communication devices, in addition to accessories, which are manufactured by various suppliers. It offers services, devices, and accessories through its owned and operated retail stores, in addition to through its Websites. T-Mobile US, Inc. also sells its devices and accessories to dealers and other third party distributors for resale through independent third-party retail outlets and various third-party Websites. The company provides its services under the T-Mobile and MetroPCS brands.
At the end of Friday’s trade, Novavax, Inc. (NASDAQ:NVAX)‘s shares surged 1.93% to $10.57.
Novavax, Inc., (NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, recently declared its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) was shown to be highly immunogenic in a guinea pig model of maternal immunization. The preclinical study was published in the journal Vaccine.
Direct immunization of infants is complicated by their immature immune systems which are unable to fight off viral infection early in life when infants are most vulnerable to RSV. In mammals, the passage of maternal antibodies to offspring is largely achieved either by in utero transplacental transfer of immunoglobulin G antibodies (IgG) or by postpartum breast-feeding of colostral milk containing high levels of IgG and sIgA.2 For human infants, maternally-derived IgG appears to be offered entirely in utero, via transplacental Fc receptor-mediated antibody transfer.2 The protective effects of human serum IgG, transferred from mothers to infants in utero,2 against a number of infections, counting influenza and pertussis, has been well-described.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology.
Sangamo Biosciences, Inc. (NASDAQ:SGMO), ended its Friday’s trading session with -4.30% loss, and closed at $7.35.
Sangamo BioSciences, Inc. (SGMO), a leader in therapeutic genome editing, declared that the company and its collaborator, Shire plc (LSE: SHP, NASDAQ: SHPG), have agreed to revise their January 2012 partnership and license agreement to expedite the development of ZFP Therapeutics for hemophilia A and B and Huntington’s disease.
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs. Its proprietary zinc finger DNA-binding protein (ZFP) technology enables precise and highly specific genome modification and gene regulation.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
